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Abstract
The development of novel therapeutics to prevent cognitive decline of Alzheimer’s disease
(AD) is facing paramount difficulties since the translational efficacy of rodent models did not
resulted in better clinical results. Currently approved treatments, including the acetylcholin-
esterase inhibitor donepezil (DON) and the N-methyl-D-aspartate antagonist memantine
(MEM) provide marginal therapeutic benefits to AD patients. There is an urgent need to
develop a predictive animal model that is phylogenetically proximal to humans to achieve
better translation. The non-human primate grey mouse lemur (Microcebus murinus) is
increasingly used in aging research, but there is no published results related to the impact of
known pharmacological treatments on age-related cognitive impairment observed in this
primate. In the present study we investigated the effects of DON and MEM on sleep-depri-
vation (SD)—induced memory impairment in young and aged male mouse lemurs. In partic-
ular, spatial memory impairment was evaluated using a circular platform task after 8 h of
total SD. Acute single doses of DON or MEM (0.1 and 1mg/kg) or vehicle were administered
intraperitoneally 3 h before the cognitive task during the SD procedure. Results indicated
that both doses of DON were able to prevent the SD-induced deficits in retrieval of spatial
memory as compared to vehicle-treated animals, both in young and aged animals Likewise,
MEM show a similar profile at 1 mg/kg but not at 0.1mg/kg. Taken together, these results
indicate that two widely used drugs for mitigating cognitive deficits in AD were partially effec-
tive in sleep deprived mouse lemurs, which further support the translational potential of this
animal model. Our findings demonstrate the utility of this primate model for further testing
cognitive enhancing drugs in development for AD or other neuropsychiatric conditions.
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Introduction
Alzheimer’s disease (AD), the most common form of dementia, is a neurodegenerative disor-
der clinically characterized by progressive deterioration of cognitive and behavioral function.
AD patients exhibit gradual memory and learning impairment, behavioral and personality
alterations, and loss of language skills, all of which greatly impairs the individual’s daily func-
tioning and ultimately leading to death [1]. Post-mortem brain sections of AD patients show
hallmark histopathological features, including extracellular amyloid-beta (Aß) peptide-con-
taining plaques and intracellular neurofibrillary tangles composed of hyperphosphorylated tau
protein [2,3]. While the exact etiology of AD is not yet determined, a cascade of pathophysio-
logical events takes place causing neuronal loss, synaptic dysfunction and neurotransmitter
deficiency as the disease progresses. This on-going event impairs crucial memory-related
structures, including hippocampus and entorhinal cortex, association cortices and the cerebral
default network, causing regional and then diffuse neuronal loss and atrophy [4,5]. This patho-
logical event causes the functional deterioration of neurotransmitter system, leading to a
decreased amount of acetylcholine, and activities of choline acetyltransferase (ChAT) and
acetylcholinesterase (AChE) in almost the entire neocortex [6]. Impairments in the glutamate
neurotransmission system, on the other hand, mediate oxidative stress and excitotoxicity [7,8],
resulting in cellular injury and apoptotic cell death.
At present, there are only four FDA-approved, marketed drugs for the symptomatic treat-
ment of AD. Three of these drugs, Donepezil (DON), galantamine and rivastigmine are acetyl-
cholinesterase (AChE) inhibitors and were developed based upon the fact that AD brains show
the highest level of cholinergic neuron degeneration in the basal forebrain, resulting in a subse-
quent reduction in cholinergic transmission to the cerebral cortex [9,10,6]. The fourth drug,
memantine (MEM), a low-to-moderate affinity non-competitive antagonist for N-methyl-D-
aspartate (NMDA) receptors was developed based upon the observation that soluble Aß oligo-
mers induce memory impairment and synapse loss by NMDA receptor activation [11,12,13].
Despite the evidence for impaired function of other neurotransmitter systems in AD [14,15],
findings of reduced cholinergic activity in the basal forebrain-cortical projections in brains of
AD patients with cognitive deficits [16] constitute the main rationale of cholinergic replace-
ment therapy as the principal therapeutic approach. The most prescribed drug DON is a highly
brain-selective, reversible, competitive AChE inhibitor that has a very prolonged half-life (~70
h) and has been shown to be somewhat effective but quite well tolerated in AD patients [17].
Large-scale clinical studies have reported variable efficacy of DON in mild, moderate and even
severe stages of AD based upon cognitive function, daily activities and behavior [18]. In pre-
clinical studies treatment with DON has been shown to improve cognitive performance in sev-
eral pharmacological models of impaired learning and memory [19,20]. MEM is the only
glutamatergic drug approved for the treatment of moderate-to-severe AD patients [21]. There
are conflicting results reported regarding the efficacy of MEM treatment. A handful of studies
have demonstrated positive results [22,23,24] whereas some other studies reported insignifi-
cant or even negative cognitive outcomes [25,26,27]. Despite the reported symptomatic and
cognitive benefits of DON and MEM in patients with mild to severe dementia [28,10,29,30],
these two drugs neither cure nor prevent progression of the disease and their reported symp-
tomatic benefits could be debated as to whether they reached clinical significance or not [31].
Animal models are essential for investigating the pathophysiological processes underlying
AD and the effects of drug therapies. Animal models, especially transgenic AD mouse models
provided valuable insight regarding the pathophysiological aspects of the disease but the suc-
cessful outcome of therapeutic trials based on data generated in these models has so far been
lacking [32,33]. For decades researchers had been searching for a valid and more predictive
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animal model to investigate the disease mechanisms, test treatments and evaluate preventive
strategies and cures. Recently, the grey mouse lemur (Microcebus murinus), a non-human pri-
mate with median survival of 5.7 years for males and a maximum longevity of 12 years, has
drawn interest as a potential model for research on ageing (see [34] for extensive review).
Age associated functional deficits have been investigated in this species and an age-dependent
cerebral atrophy was found to correlate with cognitive impairment. More specifically, the
impairment of spatial memory performances was related to the atrophy of the hippocampus
and entorhinal cortex in older animals [35]. More recently, it has been demonstrated that
about half of the old mouse lemurs displayed a specific deficit in long-term memory retention
but not in acquisition in a visual discrimination task [36].
The challenge paradigm, namely sleep-deprivation (SD), used in this study is an established
method to induce transient cognitive impairment and has been used in many preclinical stud-
ies [37,38,39]. A number of publications reported that this procedure effectively induces tem-
porary cognitive deficits analogous to those shown by patients with AD-like dementia [40]. In
a previous study in adult mouse lemurs, we effectively demonstrated the disruptive effects of
the SD on spatial memory retrieval, a cognitive function that is affected in AD patients as the
disease progresses [41]. SD specifically reduces cortical ACh levels [42], and alters NMDA
receptors [43] what may, at least partially, contribute to spatial memory impairment observed
after SD. Both observations make this challenge appropriate when targeting an AChE inhibitor
such as DON and an NMDA receptors antagonist such as MEM.
We therefore have examined the efficacy of two above-mentioned drugs in the grey mouse
lemur, which is phylogenetically proximal to the human species and bears the natural inci-
dence of AD-like pathologies in some aged animals. To our knowledge, there has been no
study performed as a back translational experiment combining the effect of age and pharmaco-
therapy on cognitive function in this novel model. In the current study, we sought to deter-
mine the extent to which spatial memory performances would be disrupted by SD challenge in
mouse lemurs and also the extent to which an acute pre-treatment of DON or MEM could
decrease the negative impact of SD on cognitive processes. Since the disruptive effects of the
SD on spatial memory retrieval in our previous study using young animals was effective but
not very potent [41], we applied this paradigm in both young and aged animals. Because aged
animals have lower performances (more errors) compared to young ones in the spatial mem-
ory protocol used in this study [35], we expected a more challenging effect of SD in old animals
compared to their young counterparts. Based upon the findings of age-related cognitive
research in this primate model, our hypothesis was that DON or MEM would be able to pre-
vent the SD-induced spatial memory deficits.
Materials and methods
Ethics statement
All experiments were performed in accordance with the Principles of Laboratory Animal Care
(National Institutes of Health publication 86–23, revised 1985) and the European Communi-
ties Council Directive (86/609/EEC). The research was conducted under the authorization
number 91–305 from the “Direction De´partementale de la Protection des Populations” and
under the approval of the Cuvier Ethical Committee (Committee number 68 of the "Comité
National de Réflexion Ethique sur l’Expérimentation Animale") under the authorization number
68–018. In accordance with the recommendations of the Weatherall report, “The use of non-
human primates in research”, special attention was paid to the welfare of the animals during
this work to minimize nociception [44].
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Animals
Sixty-nine male mouse lemurs were used in these experiments. The experiments were per-
formed in both young (2 to 3 years old) and aged (6 to 7 years old) animals. They were born
and raised in the laboratory breeding colony of Brunoy (MNHN, France, license approval N˚
A91.114.1) from a stock originally derived from the south-western coast of Madagascar 46
years ago. The animals were disease free and the general condition of captivity was maintained
under constant temperature of 24–26˚C and relative humidity of 55%. Measured food and
water were allocated to each animal. The daily food allocation consists of fresh banana, apple
and a hand-made mixture of cereals, eggs and milk. Animals were kept in alternating 6-month
period of long-days (light:dark 14:10) and short-days (light:dark 10:14). Mouse lemurs were
housed in individual cages enriched with tree branches and wooden nest.
Experimental design
All the experiments were performed during the long-day photoperiod (lights on at 08:00 and
off at 22:00). We induced transient reversible cognitive impairment by 8 h of total SD and spa-
tial memory performance was measured using a circular platform test. In DON experiment 13
young animals (0.1mg/kg, n = 6; 1mg/kg, n = 7) and 13 aged animals (0.1mg/kg, n = 6; 1mg/
kg, n = 7) were used. In MEM experiment, 13 young (0.1mg/kg, n = 6; 1mg/kg, n = 7) and 15
aged animals (0.1mg/kg, n = 7; 1mg/kg, n = 8) and in vehicle (Physiological saline) treated
experiment 8 young and 6 aged animals were used. All the animals underwent training during
day 1 (pre-SD session) and 8h of total SD was performed on day 2 followed by testing immedi-
ately after the SD challenge (post-SD session). DON, MEM or saline was injected intraperito-
neally 3h before the end of the SD or before the onset of the cognitive function test (Fig 1).
Circular platform test
Spatial performances were assessed in a circular platform apparatus [35] which is a modified
version of Barnes maze especially adapted for mouse lemurs. Briefly, the circular platform is
divided into 12 compartments with 12 equally spaced open circular holes (3 cm from perime-
ter) where a goal box can be affixed for the escape of the animal. The platform is fixed over a
spring rotator so it could rotate freely in both directions, to avoid the use of intra-maze cues
between successive trials. The whole platform is surrounded by a 15 cm high white wall with a
transparent Plexiglas ceiling that allows the mouse lemur to see the extra-maze visual cues.
The apparatus is surrounded by a black curtain hung from a square metallic frame, the ceiling
of which is a one-way mirror to allow observation for the experimenter. Twelve objects are
Fig 1. Experimental design including photoperiod. White bar indicates the light-on period and black bar indicate the light-off period.
Training started at 16:00 on day 1 and 8h of sleep deprivation (SD) started at 8:00 on day 2, the test was performed immediately after SD on
day 2 and DON, MEM or Saline injected 3h before the test.
https://doi.org/10.1371/journal.pone.0184822.g001
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attached along the inner surface of the frame to serve as visual cues. The starting box is an
open-ended dark cylinder positioned in the center of the platform.
In all experiments, training trials (day 1) consisted of 4 trials of maximum 10 min, with an
inter-trial interval of 5 min. During the first 2 trials, the animals were habituated in the maze
with only one open compartment that contains the goal box and rest of the compartment was
closed by thick white paper board. During the third and fourth trial, all the compartments
were open and only one compartment gave access to the goal box (the target). Testing con-
sisted of 2 trials of maximum 10 min, in the same condition as the last trials of the training
day. Each trial started with the placement of animal in the starting box at the center of the
maze. After 60 sec, the box was removed to release the animal. The aim of the tests was to
reach the goal box positioned beneath one of the 12 compartments. The position of the target
was fixed for each animal throughout the test during day 1 and day 2. When the animal
reached the target, the trial was stopped and the animal was allowed to remain in the goal
box for 2 min. Performance was assessed by the number of errors (entering the four limbs in
an incorrect compartment), the latency (the total time required by the animal to reach the tar-
get), the rank of the target zone (two adjacent quadrants surrounding either side of the goal-
box containing quadrant; the rank was measured by the number of errors to reach the target
zone), and the number of repetition (entry in the same quadrant more than one time) during
the testing. Results are expressed by day, each day representing the mean of the two trials of
the day.
SD challenge
Mouse lemurs were subjected to 8h total SD (8:00–16:00) starting at the onset of light period
(usual resting phase). The total SD was carried out in the first part of the light period because
the sleep is at its maximum during this period [45]. During the whole SD period, mouse
lemurs were under constant visual observation in their home cage. The nest and the tree
branches were removed from the cage for proper visualization of the animals. SD was achieved
by gentle handling, which consists of a standardized procedure of tapping on the cage, moving
the index finger in front of the cage and gently shaking the cage if required. Gentle handling
was performed if the animal shows signs of sleep such as eye closer, behavioral arrest more
than 60 s or huddled body posture. When the above measures were not sufficient to keep the
animals awake the front door was opened and closed to stimulate the animals. The electroen-
cephalographic recording confirmed that these interventions keep the animals in a state of
wakefulness for 8 h in our previous study [41].
Drug administration
DON hydrochloride or MEM hydrochloride (generous gift from Dr. Darrel Pemberton, Jans-
sen pharmaceuticals, B-2340, Beerse, Belgium) was dissolved freshly each day in physiological
saline to a concentration of 1mg or 10mg/mL (20 μl of tween 80 was added to DON for com-
plete dissolution). DON and MEM (0.1 and 1mg/kg) were injected intraperitoneally (i.p.) to
young and aged mouse lemurs 3 h before the end of sleep deprivation and the onset of cogni-
tive function test.
Rationale for dose choice
DON and MEM doses were chosen to obtain a similar exposure in mouse lemurs as observed
at steady state in humans after therapeutic doses. For DON, plasma steady state concentrations
of 22.8 and 45.0 ng/mL are reported for 5 and 10 mg/d, respectively [27]. For MEM, plasma
steady state concentrations range from 19 to 77 ng/mL after 5 and 20 mg/d, respectively
Donepezil or memantine limit sleep-deprivation-induced memory deficit in young and aged non-human primate
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[46,47]. Based on the data from a preliminary pharmacokinetic (PK) study study in grey
mouse lemurs, two population PK models were built, one for each drug (not published), using
NONMEM 7.2 (Icon Development Solutions, Hanover, Maryland). With these PK models,
concentration profiles for different doses of DON and MEM were simulated, eventually lead-
ing to the selection of the dose that would satisfy the aforementioned criterion, i.e.0.1 and 1
mg/kg.
Statistical analysis
For all statistical assessments, data were first assessed for normality using GraphPad Prism
software (version 5.01; GraphPad Software Inc. CA, USA). Effect of sessions was evaluated by
paired Wilcoxon signed rank test (comparing condition during pre-SD session to condition
during post-SD session). To compare the effect of SD between young and aged animals in
saline condition, we tested the variation in number of errors between day 1 and day 2 in young
vs aged animals (number of errors during day 2—number of errors during day 1). Test was
performed using a non-parametric Mann-Whitney rank comparison. A p-value <0.05 was
considered as significant. All values are given as median and interquartile (IQ: lower quartile–
upper quartile) in the text and are represented as box plots in figures.
Results
DON effect on SD-induced cognitive deficits in young animals
When the animals under SD were treated with vehicle, they committed significantly more
errors during the day 2 trials (testing day) than during the day 1 trials (median: 2.5, IQ:
1.6–3.5 for day 1; median: 3.75, IQ: 2.6–5.3 for day 2, p = 0.021; Fig 2A). This SD-induced
increase in the number of errors in the saline group was not observed in the 0.1mg/kg DON
injected group (median: 4.25, IQ: 1.88–6.25 for day 1; median 1.5, IQ: 0.75–3.5, p = 0.247)
or 1mg/kg DON injected group (median: 4.5, IQ: 1.5–5 for day 1, median: 3, IQ: 2.5–3.5
for day 2, p = 0.734, Fig 2A). Between groups analyses of data for day 1 or day 2 did not
show any significant difference. No significant differences were observed for the latency
(p = 0.843, Fig 2B), the rank zone (p = 0.232, Fig 2C) and for the number of repetitions
(p = 0.824, Fig 2D) between day 1 and day 2 in the saline-treated group. Both doses of
DON did not show any significant difference for latency, rank zone or number of errors
between day 1 and day 2. Acute injection of DON 0.1 and 1mg/kg prevented the SD-
induced retrieval errors.
MEM effect on SD-induced cognitive deficits in young animals
Fig 2 shows the effects of MEM on spatial memory deficits in young animals. The observed sig-
nificant increase in the number of errors on day 2 in saline treated animals was prevented by
acute treatment with MEM 0.1mg/kg (median: 3, IQ: 2.88–5.25 for day 1; median: 6., IQ: 3.5–
7.38 for day 2, p = 0.312; Fig 2A) or 1mg/kg (median: 4, IQ: 3.5–6.5 for day 1; median: 4, IQ:
1–5.5 for day 2, p = 0.552; Fig 2A). Like for the saline treated group, no significant differences
were observed in MEM groups for the latency, rank zone or number of repetitions between
day 1 and day 2 (Fig 2B–2D). Acute injection of MEM at 0.1 and 1mg/kg prevented the SD-
induced retrieval errors.
DON effect on SD-induced cognitive deficits in aged animals
As shown in Fig 3A, saline treated-old animals made a significantly higher number of errors
during day 2 trials as compared to day 1 trials (median: 3.75, IQ: 2–6.38 for day 1; median: 9,
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IQ: 4.63–11.50 for day 2, p = 0.035). Analysis of data showed that the number of errors com-
mitted during day 2 in the DON groups administered with 0.1mg/kg i (median: 6.25, IQ:
4.75–11 for day 1, median: 5, IQ: 3–8.75 for day 2, p = 0.843) and 1mg/kg i (median: 4.5, IQ:
2.5–6 for day 1, median: 3.5, IQ: 1.5–4 for day 2, p = 0.141) were not significantly different in
comparison to day 1. The latency for saline treated- animals and DON treated- animals did
not show a significant difference between day 1 and day 2 (saline, p = 0.687; DON 0.1mg/kg,
p = 0.437; DON 1mg/kg, p = 0.109; Fig 3B). The number of rank zone in saline-treated ani-
mals in day 2 was higher as compared to day 1 and was closed to the chosen level of signifi-
cance (p = 0.057) whereas the number of rank zone in both doses of DON injected animals
was not different between day 1 and day 2 (DON 0.1mg/kg, p = 1.00; DON 1mg/kg,
p = 0.141; Fig 3C). The saline-treated old animals showed a significant higher number of rep-
etitions on day 2 as compared to day 1 (p = 0.034). This was not observed in either group of
DON injected animals (0.1mg/kg, P = 0.375; or 1mg/kg, p = 0.054; Fig 3D). The acute injec-
tion of DON (0.1 or 1mg/kg) was able to prevent SD-induced impairment of memory
retrieval in old animals.
Fig 2. Effects of donepezil (DON) and memantine (MEM) on sleep-deprivation induced spatial memory performances in circular
platform test of young grey mouse lemurs showing median. (A) number of errors, (B) latency, (C) rank zone, and (D) number of
repetitions. Significant differences for the comparison of day 1 and day 2 (Wilcoxon signed rank test) are indicated as * (p<0.05).
Performance was assessed by the number of errors (entering the four limbs in an incorrect compartment), the latency (the total time required
by the animal to reach the target), the rank of the target zone (two adjacent quadrants surrounding either side of the goal-box containing
quadrant; the rank was measured by the number of errors to reach the target zone), and the number of repetition (entry in the same quadrant
more than one time) during the testing.
https://doi.org/10.1371/journal.pone.0184822.g002
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MEM effect on SD-induced cognitive deficits in aged animals
The MEM 0.1mg/kg-injected group also showed a significant higher number of errors at day 2
as compared to day 1 (median: 2, IQ: 0.5–2.5 for day 1; median: 6, IQ: 5.5–9.5 for day 2,
p = 0.041). In contrast to vehicle- and MEM 0.1mg/kg- injected groups, the number of errors
observed in the MEM 1mg/kg -injected group did not differ between day 1 and day 2 (median:
4, IQ: 1.63–6 for day 1, median: 4.5, IQ: 3.13–8.75 for day 2, p = 0.361). Latency for saline-
treated animals and MEM-treated animals did not show any significant difference between
day 1 and day 2 (Saline, p = 0.687; MEM 0.1mg/kg, p = 0.932; MEM 1mg/kg, p = 1.00; Fig 3B).
For both doses, the number of rank zone of MEM injected animals did not show any signifi-
cant difference between day 1 and day 2 (MEM 0.1mg/kg, p = 0.149; MEM 1mg/kg, p = 0.611;
Fig 3C). Although the number of repetitions at day 2 in MEM 0.1mg/kg injected-animals was
not significantly different from day 1, a trend toward a statistically significant effect was noted
(p = 0.062, Fig 3D). The number of repetitions in MEM 1mg/kg-injected animals did not differ
significantly between day 1 and day 2. The High dose of MEM (1mg/kg) but not the low dose
(0.1mg/kg) was noted to prevent the SD-induced impairment of memory retrieval in old
animals.
Fig 3. Effects of donepezil (DON) and memantine (MEM) on sleep-deprivation induced spatial memory performances in circular
platform test of aged grey mouse lemurs showing median. (A) number of errors, (B) latency, (C) rank zone, and (D) number of
repetitions. Significant differences for the comparison of day 1 and day 2 (Wilcoxon signed rank test) are indicated as * (p<0.05).
Performance was assessed by the number of errors (entering the four limbs in an incorrect compartment), the latency (the total time required
by the animal to reach the target), the rank of the target zone (two adjacent quadrants surrounding either side of the goal-box containing
quadrant; the rank was measured by the number of errors to reach the target zone), and the number of repetition (entry in the same quadrant
more than one time) during the testing.
https://doi.org/10.1371/journal.pone.0184822.g003
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Comparison of the effects of SD on number of errors between young and
aged animals in saline condition
The variation in number of errors between day 1 and day 2 is significantly increased in aged
animals median: 7.0, IQ: 2.5–7.5) compared to young (median: 1.0, IQ: 0.5–1.75) (p = 0.0011).
Discussion & conclusion
In a previous study we demonstrated that 8h of SD by gentle handling was a valid paradigm to
induce a transient impairment of spatial memory performances in young mouse lemurs [41].
The present study confirms our former findings and demonstrates that SD-induced spatial
memory impairment can be reversed in both young and aged animals by an acute administra-
tion of DON and MEM.
The current treatments of AD are designed either to augment the cholinergic function by
inhibiting the enzyme AChE or to prevent the excitatory effect of NMDA receptors. A number
of preclinical studies have reported cognition-enhancing effects of DON [48,49,50,51] follow-
ing chronic administration in mouse models of AD. Few preclinical studies have tested the
effects of acute administration of DON or MEM on memory performances [52,53]. Our pres-
ent study is one of the first to test the acute effect of these clinically used drugs in a model
which is phylogenitically proximal to human and an important natural model relevant for
aging or neurodegenerative diseases.
We believe that our challenge paradigm of SD by gentle handling is a valid protocol for pro-
ducing a transient reversible cognitive impairment without causing much stress. SD proce-
dures in rodents are normally performed either by moving treadmills or rotating wheels or
"disk-over-water" method in which the method itself incurs a significant amount of stress in
addition to SD challenge. Moreover, we have successfully established this challenge paradigm
to induce a spatial memory impairment in a previous study in grey mouse lemurs [41] and
electroencephalographic recordings have shown that this intervention effectively maintains
the animals in a state of wakefulness for several hours both in mouse lemurs [41] and rats [54],
without substantial changes in serum cortisol level in mice [55]. Together, our data support
the utility of SD as a suitable paradigm for the induction of a cognitive impairment not only in
young animals but also in aged animals.
In the present study, DON was shown to be effective in young and aged animals; at both
low (0.1mg/kg) and high (1mg/kg) doses, DON was able to prevent the significant increase of
SD-induced spatial memory retrieval errors as compared to vehicle treated animals (Figs 2A
and 3A). Our finding is consistent with the finding of [56] indicating that DON at doses of 0.5
and 1 mg/kg was effective in reversing scopolamine-induced spatial memory performances in
rats submitted to a water maze task. By and large, DON has shown to reverse scopolamine-
induced learning deficits in reference and working memory tests in rodents [57,20,58]. Inter-
estingly, a study performed in transgenic AD mice revealed that sub-chronic administration of
DON for 2 weeks concomitantly improved the cognitive deficits along with the dose-depen-
dent decrease of brain soluble and insoluble Aβ40 and 42 [59]. Consistent with preclinical
studies, DON has been shown to counteract the negative impact of SD on cognitive function
in a group of healthy individuals whose cognitive performance was greatly impaired by SD
[60,61]. Previous studies using cholinomimetics and AChE inhibitors have reported that these
drugs were able to improve memory function at low doses but higher doses were shown to
impair memory function, thereby resulting in an inverted U-shaped dose-response curve
[62,63]. Despite the fact that we only used two doses, in the present study, we did not find this
bell-shaped curve since both the low and high doses were able to reduce the SD-induced mem-
ory impairment in young and aged animals.
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The excitatory amino acid, glutamate, acts through NMDA receptors and these receptors
play an important role in calcium homeostasis, synaptic plasticity, and learning and memory
[64]. Dysregulation of NMDA receptors have been found in AD, and it has been reported that
NMDA receptor-expressing neurons are more vulnerable to AD-related insults [65,66]. A
number of studies have examined the effect of MEM on cognitive functions following different
protocols in different animal models [48,49,67] and most of them reported positive effects of
MEM on cognitive function. In the present study, acute treatment with MEM at 0.1 and 1mg/
kg improved the memory retrieval performances in young animals that were perturbed by a
SD challenge. However, in aged animals, MEM failed to improve the spatial memory perfor-
mances induced by SD challenge at 0.1 mg/kg. Only the dose of 1 mg/kg successfully reversed
the SD-induced memory retrieval impairment. This suggests that the SD paradigm is more
challenging for aged animals compared to young ones. It is worth mentioning here that low
doses of MEM have been found to impair the retrieval memory after 24 h of learning in adult
rat [26]. Interestingly, [50] showed that acute treatment with MEM improved working and
spatial memory dysfunction in transgenic AD mice, which is in line with our findings. Also
consistent with our results, a recent study by [68] investigated the effect of MEM on SD-
induced cognitive impairment in Octodon degus, a rodent model that exhibits a natural occur-
rence of some AD-related neuropathologies. Their findings indicated that MEM was able to
prevent reference and working memory impairment caused by SD in both young and aged
animals. Several clinical studies in healthy volunteers have examined the effect of MEM after a
single dose on mood, attention, immediate or delayed verbal memory and visuospatial mem-
ory and reported either weak positive effect or a negative impact depending on the tasks used
[69,70,71]. In contrast, some clinical studies in patients with moderate to severe AD demon-
strate that MEM was able to slow cognitive decline [72,73].
From a pharmacokinetic perspective, two possible limitations to the interpretation of the
results are worth mentioning. The first is that the PK modelson which the doses were chosen
were built from PK data obtained in young adults: it is possible that age may affect the pharma-
cokinetics of the drugs. Hence, the same dose could in theory give different concentration lev-
els in young and aged mouse lemurs (and therefore could explain, at least in part, the lack of
efficacy in spatial memory performance shown by MEM at the lower dose). The second limita-
tion is the lack of information available regarding the distribution properties of DON and
MEM in mouse lemurs, and especially the drug penetration into the brain. Doses for both
compounds were chosen to reflect plasma steady state concentrations observed in humans,
but even when plasma concentrations match perfectly across species, it is not possible to infer
the amount of drug actually reaching AChE enzymes and NMDA receptors in the brain. With
regard to these limitations, further and specific studies are required. It is worth mentioning
here that we avoided sampling blood during the sleep deprivation procedure to avoid unneces-
sary stress to the mouse lemurs that could hamper the cognitive performance of the animals.
To obtain the optimum translational efficacy, a novel therapeutic agent should be tested in
an animal model that has a satisfactory level of construct, face and predictive validity. Clinical
efficacy and drug toxicity translated from preclinical rodent models to humans has not always
resulted in a reliable degree of predictability with regard to clinical outcome. If transgenic
mouse models of AD have been providing invaluable information regarding molecular and
pathophysiological aspects of the disease, their translational efficacy has been to date disap-
pointing. Independent of the problem of underpowered studies with a too small number of
animals that may partly explain the lack of translatability noted when one use transgenic mice
relevant for AD, an ideal preclinical approach should select the most relevant animal model
that can provide a reflective behavioural task measuring higher-level cognitive functions in
order to achieve the highest translational efficacy. Considering the complexity of the human
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brain, and the high genetic homology between non-human primates and human species, the
non-human primate mouse lemurs may serve as a potential model for evaluating cognition-
enhancing therapeutic agents. In terms of construct validity, some aged mouse lemurs show
most of the AD-related neuropathological hallmarks as demonstrated by pathological studies
on brain section [74]. In our previous study we demonstrated that spatial memory perfor-
mances could be impaired transiently in young animals by SD [41], which was more challeng-
ing in aged animals as suggested by the present study. Indeed, SD impacts more aged animals
as revealed by their higher increase in number of errors between day 1 and day 2 compared to
young. Moreover, [35] and [75], using magnetic resonance imaging and behavioural studies,
recently demonstrated that both executive function and spatial memory decline with age in
this primate. This provides partial face validity of this animal model. The interest of using
non-human primates to obtain the optimum translational efficacy is supported by similar
studies in other non-human primates. In the study by [76], testing the effects of memantine
and galantamine on cognitive performances in aged rhesus macaques, the authors report mild
beneficial effects on some aspects of cognitive performance in aged animals. This observation
is in accordance with the present results and in agreement with the human observations
with these drugs, but in contrast to the more positive effects reported in the rodent literature.
These data suggest that the nonhuman primate might have more predictive validity for drug
development in this area than comparable rodent assays. This higher predictive validity can
be explained by the closer phylogenic proximity of primates, but also maybe by the higher
inter-individual variability that characterizes primates and may help mimic better human
variability.
In conclusion, the present study, to our knowledge, is the first in which acute administra-
tion of t two approved drugs for treating cognitive function in AD patients has been shown to
improve spatial memory impairment produced by a sleep deprivation procedure in the non-
human primate grey mouse lemur. Although the SD challenge could not induce a learning-as
opposed to retrieval- deficit in spatial memory [41], the symptomatic benefit observed after a
single administration of DON or MEM in the present study give more confidence in the pre-
dictive validity of this model. Further studies are required to achieve a higher level of validation
by including the testing of other cognitive domains and the use of different challenges to
induce transient cognitive impairment and understand the molecular and cellular mechanisms
subserving these alterations.
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